BeOne Medicines' Potential Chemotherapy-Free Lymphoma Treatment Meets Primary Endpoint in Phase 3 Study
MT Newswires Live06-30 18:40
BeOne Medicines' (ONC) Brukinsa met its primary endpoint of progression-free survival in a phase 3 study evaluating the drug as a potential treatment in combination with rituximab for mantle cell lymphoma, the company said Tuesday.
The chemotherapy-free drug combination showed "a highly statistically significant and clinically meaningful improvement" versus standard of care, the company said.
The safety profile was consistent with that of both medicines, the company said.
Mantle cell lymphoma is a rare and typically aggressive type of B-cell non-Hodgkin lymphoma, mostly affecting older adults, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
